13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001917529
Total reported value
$881.3M
$881.3M
8 檔
95.8%
The Q4 2025 SEC filing reveals that Atlas Venture Life Science Advisors, LLC held a total portfolio value of $881.3M, covering 8 public equity positions.
In Q4 2025, Atlas Venture Life Science Advisors, LLC adopted a defensive or profit-taking posture, trimming 4 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc | Stock-Other | 41.91% | -11.21% | -4.83% | |
| 2 | DYN | Dyne Therapeutics Inc | Stock-Other | 20.64% | -3.81% | — | |
| 3 | SION | Sionna Therapeutics Inc | Stock-Other | 14.24% | -0.25% | -17.15% | |
| 4 | IRON | Disc Medicine Inc | Stock-Other | 13.90% | +0.31% | -29.34% | |
| 5 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 6.91% | — | -0.28% | |
| 6 | KRRO | Korro Bio Inc | Stock-Other | 1.05% | -0.19% | — | |
| 7 | QTTB | Q32 Bio Inc | Stock-Other | 0.80% | +2.23% | — | |
| 8 | ✓ | Stock-Other | 0.54% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | DYN | Dyne Therapeutics Inc | +5.3% | — | Unchanged |
| 2 | KYMR | Kymera Therapeutics Inc | +5.1% | -4.83% | Trim |
| 3 | DAWNGBX | Day One Biopharmaceuticals I | +0.9% | -0.28% | Trim |
| 4 | QTTB | Q32 Bio Inc | +0.3% | — | Unchanged |
| 5 | SION | Sionna Therapeutics Inc | +0.1% | -17.15% | Trim |
| 6 | IRON | Disc Medicine Inc | -4.9% | -29.34% | Trim |
| 7 | KRRO | Korro Bio Inc | -6.2% | — | Unchanged |
| 8 | GBIOGBX | Generation Bio Co | — | EXIT | Sold out |
| 9 | ✓ | — | NEW | New buy | |
| 10 | IMA | Imagenebio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Atlas Venture Life Science Advisors, LLC reported a total U.S. public equity portfolio value of $881.3M across 8 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KYMR, DYN, SION) accounted for 95.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
市值: $4.7M
Top Position Liquidated / Trimmed
GBIOGBX
前期市值: $5.1M
During Q4 2025, Atlas Venture Life Science Advisors, LLC's top holdings by market value included KYMR (41.9%)、DYN (20.6%)、SION (14.2%). The largest single position, KYMR, represented 41.9% of total portfolio value.
In Q4 2025, Atlas Venture Life Science Advisors, LLC made 7 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 4 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.